



ANTARES PHARMA TO PRESENT AT THE 15TH ANNUAL BANK OF AMERICA MERRILL LYNCH HEALTH CARE CONFERENCE

EWING, NJ, MAY 10, 2012 -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Jack Howarth, Vice President of Corporate Affairs, will present at the 15th Annual Bank of America Merrill Lynch Health Care Conference on Thursday, May 17, 2012 at 12:00 pm PDT.

A live webcast of the presentation will be available via the "Investor Relations" page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 60 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the U.S. and Canada. Antares' portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the development and manufacturing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company's corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company's transdermal systems and drug/device combination products.

Contacts:

Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com

Westwicke Partners, LLC
John Woolford
(443) 213-0506
john.woolford@westwicke.com